Views | |
---|---|
Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: Updated survival results and subgroup analyses from the BEACON study | 51 |
January 2024 | February 2024 | March 2024 | April 2024 | May 2024 | |
---|---|---|---|---|---|
Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: Updated survival results and subgroup analyses from the BEACON study | 11 | 30 | 1 | 7 | 2 |
Views | |
---|---|
artconlli_a2021_tabernero_josep_encorafenib_plus_cetuximab.pdf | 12 |
Views | |
---|---|
United States | 10 |
China | 7 |
Spain | 5 |
Views | |
---|---|
Barcelona | 5 |
Oakland | 5 |
Shanghai | 5 |
Menlo Park | 3 |
Fairfield | 1 |
Guangzhou | 1 |
Mountain View | 1 |
Xingtai | 1 |